开发多糖涂层层的双氧化物纳米复合材料,用于增强口服胰岛素的输送
Huiwen Pang1, Youzhi Wu1, Yang Chen2
1Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
Drug delivery and translational research
|January 12, 2024
概括
研究人员开发了一种新的双涂层纳米复合材料,用于口服胰岛素的输送,改善其在胃中的稳定性,并增强糖尿病小鼠的葡萄糖降低. 这种酸盐和酸盐涂层层的双氧化物系统对有效的糖尿病管理有很大的希望.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 口服胰岛素提供了糖尿病的显著治疗优势,通过模仿内源性胰岛素途径来控制肝脏的葡萄糖生产.
- 层状双氧化物 (LDH) 纳米颗粒由于生物相容性和负载能力而有望用于药物输送,但它们的口服有效性受到胃酸的阻碍.
- 现有的口服胰岛素输送系统在胃肠道中面临着稳定性和有效性的挑战.
研究的目的:
- 开发一种稳定的口服胰岛素输送系统,使用双层涂层的双氧化物 (LDH) 纳米复合材料.
- 为了克服胃中酸性降解的局限性,提高胰岛素的输送.
- 在体外和体外评估新型口服胰岛素输送系统的疗效和生物相容性.
主要方法:
- 层层的双氧化物 (LDH) 纳米颗粒装载了胰岛素,随后使用层层的方法涂上了酸盐 (Alg) 和酸盐 (Chi),形成了Alg-Chi-LDH@INS.
- 分析了纳米复合材料的特性 (大小,电荷,分散性).
- 在酸性条件下使用紫外线可见光谱学研究了体外胰岛素释放.
- 用Caco-2细胞进行流动细胞计量来评估细胞吸收率.
- 在体内低血糖效应和生物相容性被评估在链毒素诱导的糖尿病小鼠中.
主要成果:
- 开发的Alg-Chi-LDH@INS纳米复合材料的尺寸为~350.8nm,负电荷为~-13.0mV,分散指数为0.228.8.
- 酸盐和酸盐涂层提供了部分保护,防止在酸性环境中突发胰岛素释放.
- 与未经修改的LDH和自由胰岛素相比,基托涂层显著增强了Caco-2细胞对胰岛素载荷的LDH的细胞吸收.
- 在糖尿病小鼠中,口服导致显著的低血糖效应 (大约在4小时内减少50%的血糖),具有良好的生物相容性.
结论:
- 双涂层Alg-Chi-LDH@INS纳米复合材料是克服口服胰岛素输送局限性的有希望的策略.
- 保护层增强了在酸性条件下的稳定性,并改善了细胞吸收,从而产生了有效的体内降糖效应.
- 这种新型纳米复合体系统显示出开发用于糖尿病治疗的有效和生物相容的口服胰岛素配方的潜力.
相关概念视频
Insulin Formulations: Types and Delivery
197
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
197
Insulin: Biosynthesis, Chemistry, and Preparation
384
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
384
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
176
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
176
Drug Delivery: Enteral Route
456
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
456


